Cancer therapy trials employing level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1

Expert Review of Molecular Diagnostics

Volumn 11, Issue 6, 2011, Pages 617-634

  Schmitt, Manfred ^a,b   Harbeck, Nadia ^c   Brünner, Nils ^d   Jänicke, Fritz ^e   Meisner, Christoph ^f   Mühlenweg, Bernd ^g,h   Jansen, Heike ^b   Dorn, Julia ^b   Nitz, Ulrike ⁱ   Kantelhardt, Eva J ^j   Thomssen, Christoph ^j  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

^e UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^f UNIVERSITY OF TÜBINGEN   (Germany)

^g Wilex Biotechnology GmbH   (Germany)

^h NANOBIOTIX   (France)

ⁱ West German Study Group (WSG)   (Germany)

^j MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

more..

Author keywords

clinical studies; clinical trials; individualized tailored cancer care; personalized cancer treatment; predictive impact; prognostic relevance; targeted therapy

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; MESUPRON; METHOTREXATE; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROGESTERONE RECEPTOR; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB; TUMOR MARKER; UNCLASSIFIED DRUG; UROKINASE; WX 671;

ABSENCE OF SIDE EFFECTS; AGE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER SIZE; CANCER SURVIVAL; DISEASE SEVERITY; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; ENZYME LINKED IMMUNOSORBENT ASSAY; HEAD AND NECK TUMOR; HISTOPATHOLOGY; HUMAN; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NONHUMAN; PANCREAS CANCER; PHASE 2 CLINICAL TRIAL (TOPIC); PROGNOSIS; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SOLID TUMOR;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; NEOPLASMS; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN STRUCTURE, SECONDARY; PROTEIN STRUCTURE, TERTIARY; TUMOR MARKERS, BIOLOGICAL; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 79960209125     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/erm.11.47     Document Type: Review

References (96)

1. Cliffton EE, Grossi CE. Fibrinolytic activity of human tumors as measured by the fibrin-plate method. Cancer 8, 1146-1154 (1955)
2. Schmitt M, Mengele K, Gkazepis A et al. Assessment of urokinase-type plasminogen activator and its inhibitor PAI-1 in breast cancer tissue: historical aspects and future prospects. Breast Care 3(S2), 3-10 (2008)
3. Schmitt M, Mengele K, Napieralski R et al. Clinical utility of level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1. Expert Rev. Mol. Diagn. 10(8), 1051-1067 (2010)
4. López-Otín C, Overall CM. Protease degradomics: a new challenge for proteomics. Nat. Rev. Mol. Cell. Biol. 3, 509-519 (2002) (Pubitemid 34733432)
5. Mengele K, Napieralski R, Magdolen V et al. Characteristics of the level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1. Expert Rev. Mol. Diagn. 10(7), 947-962 (2010)
6. Ulisse S, Baldini E, Sorrenti S, D'Armiento M. The urokinase plasminogen activator system: a target for anti-cancer therapy. Curr. Cancer Drug Targets 9, 32-71 (2009)
7. Annecke K, Schmitt M, Euler U et al. uPA and PAI-1 in breast cancer: review of their clinical utility and current validation in the prospective NNBC-3 trial. Adv. Clin. Chem. 45, 31-45 (2008)
8. O'Grady P, Lijnen HR, Duffy MJ. Multiple forms of plasminogen activator in human breast tumors. Cancer Res. 45(12 Pt 1), 6216-6218 (1985) (Pubitemid 16224783)
9. Harbeck N, Schmitt M, Vetter M et al. Prospective biomarker trials Chemo-N0 and NNBC-3 Europe validate the clinical utility of invasion markers uPA and PAI-1 in node-negative breast cancer. Breast Care 3(S2), 11-15 (2008)
10. Harbeck N, Schmitt M, Paepke S, Allgayer H, Kates RE. Tumor-associated proteolytic factors uPA and PAI-1: critical appraisal of their clinical relevance in breast cancer and their integration into decision-support algorithms. Crit. Rev. Clin. Lab. Sci. 44, 179-201 (2007)
11. Harbeck N, Kates RE, Schmitt M et al. Urokinase-type plasminogen activator and its inhibitor type 1 predict disease outcome and therapy response in primary breast cancer. Clin. Breast Cancer 5, 348-352 (2004) (Pubitemid 40109640)
12. Harbeck N, Kates RE, Gauger K et al. Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-I: novel tumor-derived factors with a high prognostic and predictive impact in breast cancer. Thromb. Haemost. 91, 450-456 (2004) (Pubitemid 38396866)
13. Harbeck N, Salem M, Nitz U, Gluz O, Liedtke C. Personalized treatment of early-stage breast cancer: present concepts and future directions. Cancer Treat. Rev. 36, 584-594 (2010)
14. van't Veer LJ, Paik S, Hayes DF. Gene expression profiling of breast cancer: a new tumor marker. J. Clin. Oncol. 23, 1631-1635 (2005) (Pubitemid 46211417)
15. Albain KS, Paik S, van't Veer L. Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assays. Breast 18(Suppl. 3), S141-S145 (2009)
16. Harris L, Fritsche H, Mennel R et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J. Clin. Oncol. 25, 5287-5312 (2007) (Pubitemid 350232263)
17. Sturgeon CM, Duffy MJ, Stenman UH et al. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin. Chem. 54(12), E11-E79 (2008) (Pubitemid 352777353)
18. Fornier M, Hudis C. Adjuvant chemotherapy for primary breast cancer. Curr. Oncol. Rep. 7, 18-22 (2005) (Pubitemid 40277586)
19. Bernard-Marty C, Cardoso F, Piccart MJ. Facts and controversies in systemic treatment of metastatic breast cancer. Oncologist 9, 617-632 (2004) (Pubitemid 39546403)
20. Harbeck N, Kates RE, Schmitt M. Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination. J. Clin. Oncol. 20, 1000-1007 (2002) (Pubitemid 34141844)
21. Harbeck N, Kates RE, Look MP et al. Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424). Cancer Res. 62, 4617-4622 (2002)
22. Jänicke F, Prechtl A, Thomssen C et al. Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. J. Natl Cancer Inst. 93, 913-920 (2001) (Pubitemid 32624648)
23. Look MP, van Putten WL, Duffy MJ et al. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J. Natl Cancer Inst. 94, 116-128 (2002) (Pubitemid 34121291)
24. Hayes DF, Bast RC, Desch CE et al. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J. Natl Cancer Inst. 88, 1456-1466 (1996) (Pubitemid 26340047)
25. Jänicke F, Pache L, Schmitt M et al. Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1. Cancer Res. 54, 2527-2530 (1994)
26. Harbeck N, Schmitt M, Meisner C et al. Final 10-year analysis of prospective multicenter Chemo-N0 trial for validation of ASCO-recommended biomarkers uPA/PAI-1 for therapy decision making in node-negative breast cancer. J. Clin. Oncol. 27, 15S(Suppl.) (2009) (Abstract 511)
27. Goldhirsch A, Glick JH, Gelber RD, Senn HJ. Meeting highlights: international consensus panel on the treatment of primary breast cancer. J. Natl Cancer Inst. 90, 1601-1608 (1998) (Pubitemid 28523434)
28. Harbeck N, Meisner C, Prechtl A et al. Level-I evidence for prognostic and predictive impact of uPA and PAI-1 in node-negative breast cancer provided by second scheduled analysis of multicenter Chemo-N0 therapy trial. Breast Cancer Res. Treat. 69, 213 (2001) (Pubitemid 33788866)
29. Thomssen C, Harbeck N, Dittmer J et al. Feasibility of measuring the prognostic factors uPA and PAI-1 in core needle biopsy breast cancer specimens. J. Natl Cancer Inst. 101, 1028-1029 (2009)
30. Malinowsky K, Ballner C, Hipp S, Berg D, Schmitt M, Becker KF. uPA and PAI-1 analysis from fixed tissues - new perspectives for a known set of predictive markers. Curr. Med. Chem. 17, 4370-4377 (2010)
31. Grebenchtchikov N, Maguire TM, Riisbro R et al. Measurement of plasminogen activator system components in plasma and tumor tissue extracts obtained from patients with breast cancer: an EORTC Receptor and Biomarker Group collaboration. Oncol. Rep. 14, 235-239 (2005)
32. Aapro MS. Adjuvant therapy of primary breast cancer: a review of key findings from the 7th international conference, St. Gallen, February 2001. Oncologist 6, 376-385 (2001) (Pubitemid 32816543)
33. Martín M, Rodríguez-Lescure A, Ruiz A et al. Randomized Phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer. J. Natl Cancer Inst. 100, 805-814 (2008) (Pubitemid 351809668)
34. Martín M, Seguí MA, Antón A et al. Adjuvant docetaxel for high-risk, node-negative breast cancer. N. Engl. J. Med. 363, 2200-2210 (2010)
35. Goldhirsch A, Glick JH, Gelber RD, Coates AS, Senn HJ. Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer. J. Clin. Oncol. 19, 3817-3827 (2001) (Pubitemid 32880060)
36. Svetlovska D, Mardiak J, Kristova V. Trastuzumab in the adjuvant treatment of breast cancer. Bratisl. Lek. Listy 108, 100-103 (2007)
37. Degenhardt T, Gluz O, Thomssen C et al. Risk group selection in primary breast cancer according to ASCO recommended biomarkers Oncotype DX and uPA/PAI-1. First experience from prospective multicenter WSG Plan B trial. Cancer Res. 70, 209S (2010) (Abstract P2-09-05)
38. Paik S, Shak S, Tang G et al. Multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. 351, 2817-2826 (2004) (Pubitemid 40051905)
39. Zujewski JA, Kamin L. Trial assessing individualized options for treatment for breast cancer, the TAILORx trial. Future Oncol. 4, 603-610 (2008)
40. Dowsett M, Cuzick J, Wale C et al. Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen, a transATAC study. J. Clin. Oncol. 28, 1829-1834 (2010)
41. Muehlenweg B, Sperl S, Magdolen V, Schmitt M, Harbeck N. Interference with the urokinase plasminogen activator system: a promising therapy concept for solid tumours. Expert Opin. Biol. Ther. 1, 683-961 (2001)
42. Setyono-Han B, Sturzebecher J, Schmalix WA et al. Suppression of rat breast cancer metastasis and reduction of primary tumour growth by the small synthetic urokinase inhibitor WX-UK1. Thromb. Haemost. 93, 779-786 (2005) (Pubitemid 40485417)
43. Nienaber V, Wang J, Davidson D, Henkin J. Re-engineering of human urokinase provides a system for structure-based drug design at high resolution and reveals a novel structural subsite. J. Biol. Chem. 275, 7239-7248 (2000) (Pubitemid 30146275)
44. Bruncko M, McClellan WJ, Wendt MD et al. Naphthamidine urokinase plasminogen activator inhibitors with improved pharmacokinetic properties. Bioorg. Med. Chem. Lett. 15, 93-98 (2005) (Pubitemid 39575790)
45. Henneke I, Greschus S, Savai R et al. Inhibition of urokinase activity reduces primary tumor growth and metastasis formation in a murine lung carcinoma model. Am. J. Respir. Crit. Care Med. 181, 611-619 (2010)
46. Joossens J, Ali OM, El-Sayed I et al. Small, potent, and selective diaryl phosphonate inhibitors for urokinase-type plasminogen activator with in vivo antimetastatic properties. J. Med. Chem. 50, 6638-6646 (2007)
47. Goldstein LJ. Experience in Phase I trials and an upcoming Phase II study with uPA inhibitors in metastatic breast cancer. Breast Care 3(S2), 25-28 (2008)
48. Heinemann V, Ebert MP, Pinter T, Bevan P, Neville NG, Mala C. Randomized Phase II trial with an uPA inhibitor (WX-671) in patients with locally advanced nonmetastatic pancreatic cancer. J. Clin. Oncol. 28, 15S(Suppl.) (2010) (Abstract 4060)
49. Goldstein LJ, Stemmer SM, Schmalfeldt B et al. Phase II, two-arm, double-blind, multicenter, randomized study of the combination of oral WX-671 plus capecitabine versus capecitabine in first-line HER2-negative metastatic breast cancer (MBC). J. Clin. Oncol. 28, 15S(Suppl.) (2010) (Abstract TPS131)
50. Schmitt M, Harbeck N, Thomssen C et al. Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy. Thromb. Haemost. 78, 285-296 (1997) (Pubitemid 27289256)
51. Schmitt M, Jänicke F, Graeff H. Tumor-associated proteases. Fibrinolysis 6(Suppl. 4), 3-26 (1992)
52. Guo Y, Higazi AA, Arakelian A et al. A peptide derived from the nonreceptor binding region of urokinase plasminogen activator (uPA) inhibits tumor progression and angiogenesis and induces tumor cell death in vivo. FASEB J. 14, 1400-1410 (2000) (Pubitemid 30439749)
53. Guo Y, Mazar AP, Lebrun JJ, Rabbani SA. An antiangiogenic urokinase-derived peptide combined with tamoxifen decreases tumor growth and metastasis in a syngeneic model of breast cancer. Cancer Res. 62, 4678-4684 (2002)
54. Boyd DD, Kim SJ, Wang H, Jones TR, Gallick GE. A urokinase-derived peptide (A6) increases survival of mice bearing orthotopically grown prostate cancer and reduces lymph node metastasis. Am. J. Pathol. 162, 619-626 (2003) (Pubitemid 36267868)
55. Damaj BB, Incardonna F, Piotrowicz R, Howell SB, Finlayson M. A6 peptide binds to CD44 and inhibits migration and metastasis of CD44+ cell lines in in vitro and in vivo studies. Presented at: American Association for Cancer Research 101st Annual Meeting. Washington, DC, USA, 17-21 April 2010 (Abstract 5120)
56. Damaj BB, Wen Y, Schneider L, Howell S, Finlayson F. A6 peptide exhibits potent anti chemotactic activity against human breast and ovarian cancer cell lines. Presented at: American Association for Cancer Research Annual Meeting. San Diego, CA, USA, 12-16 April 2008 (Abstract 1170)
57. Franco P, Vocca I, Carriero MV et al. Activation of urokinase receptor by a novel interaction between the connecting peptide region of urokinase and avb5 integrin. J. Cell Sci. 119(Pt 16), 3424-3434 (2006) (Pubitemid 44405226)
58. Mishima K, Mazar AP, Gown A et al. A peptide derived from the non-receptor-binding region of urokinase plasminogen activator inhibits glioblastoma growth and angiogenesis in vivo in combination with cisplatin. Proc. Natl Acad. Sci. USA 97, 8484-8489 (2000) (Pubitemid 30639699)
59. van Troostenburg AR, Lee D, Jones TR et al. Safety, tolerability and pharmacokinetics of subcutaneous A6, an 8-amino acid peptide with anti-angiogenic properties, in healthy men. Int. J. Clin. Pharmacol. Ther. 42, 253-259 (2004) (Pubitemid 38679013)
60. Berkenblit A, Matulonis UA, Kroener JF et al. A6, a urokinase plasminogen activator (uPA)-derived peptide in patients with advanced gynecologic cancer: a Phase I trial. Gynecol. Oncol. 99, 50-57 (2005) (Pubitemid 41354582)
61. Ghamande SA, Silverman MH, Huh W et al. A Phase 2, randomized, double-blind, placebo-controlled trial of clinical activity and safety of subcutaneous A6 in women with asymptomatic CA125 progression after first-line chemotherapy of epithelial ovarian cancer. Gynecol. Oncol. 111, 89-94 (2008)
62. Navaratna D, Menicucci G, Maestas J, Srinivasan R, McGuire P, Das A. A peptide inhibitor of the urokinase/urokinase receptor system inhibits alteration of the blood-retinal barrier in diabetes. FASEB J. 22, 3310-3317 (2008)
63. Koh HJ, Bessho K, Cheng L et al. Inhibition of choroidal neovascularization in rats by the urokinase-derived peptide A6. Invest. Ophthalmol. Vis. Sci. 45, 635-640 (2004) (Pubitemid 38140524)
64. Koh HJ, Freeman WR, Azen SP et al. Effect of a novel octapeptide urokinase fragment, A6, on experimental choroidal neovascularization in the monkey. Retina 26, 202-209 (2006) (Pubitemid 44400718)
65. Duffy MJ, O'Grady P, Devaney D, O'Siorain L, Fennelly JJ, Lijnen HJ. Urokinase-plasminogen activator, a marker for aggressive breast carcinomas. Preliminary report. Cancer 62, 531-533 (1988)
66. Jänicke F, Schmitt M, Ulm K, Gossner W, Graeff H. Urokinase-type plasminogen activator antigen and early relapse in breast cancer. Lancet 2(8670), 1049 (1989) (Pubitemid 19257967)
67. Jänicke F, Schmitt M, Graeff H. Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer. Semin. Thromb. Hemost. 17, 303-312 (1991)
68. Igbokwe A, Lopez-Terrada DH. Molecular testing of solid tumors. Arch. Pathol. Lab. Med. 135, 67-82 (2011)
69. Dotan E, Goldstein LJ. Optimizing chemotherapy regimens for patients with early-stage breast Cancer Clin. Breast Cancer 10(Suppl. 1), E8-E15 (2010)
70. Sweep CG, Geurts-Moespot J, Grebenschikov N et al. External quality assessment of trans-European multicentre antigen determinations (enzyme-linked immunosorbent assay) of urokinase-type plasminogen activator (uPA) and its type 1 inhibitor (PAI-1) in human breast cancer tissue extracts. Br. J. Cancer 78, 1434-1441 (1998) (Pubitemid 28517539)
71. Jankun J, Skotnicka M, Lysiak- Szydowska W, Al-Senaidy A, Skrzypczak- Jankun E. Diverse inhibition of plasminogen activator inhibitor type 1 by theaflavins of black tea. Int. J. Mol. Med. 27, 525-529 (2011)
72. Madsen JB, Dupont DM, Andersen TB et al. RNA aptamers as conformational probes and regulatory agents for plasminogen activator inhibitor-1. Biochemistry 49, 4103-4115 (2010)
73. Andreasen PA. PAI-1 - a potential therapeutic target in cancer. Curr. Drug Targets 8, 1030-1041 (2007) (Pubitemid 47578151)
74. Henri NL, Hayes DF. Uses and abuses of tumor markers in the diagnosis, monitoring, and treatment of primary and metastatic breast Cancer Oncol. 11, 541-552 (2006). (Pubitemid 43967610)
75. Harris TJ, McCormick F. The molecular pathology of cancer. Nat. Rev. Clin. Oncol. 7, 251-265 (2010)
76. Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N. Engl. J. Med. 360, 790-800 (2009)
77. Gilligan TD, Hayes DF, Seidenfeld J, Temin S. ASCO Clinical Practice Guideline on uses of serum tumor markers in adult males with germ cell tumors. J. Oncol. Pract. 6, 199-202 (2010)
78. Locker GY, Hamilton S, Harris J et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J. Clin. Oncol. 24, 5313-5327 (2006) (Pubitemid 46631379)
79. Sturgeon CM, Duffy MJ, Hofmann BR et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in liver, bladder, cervical, and gastric cancers. Clin. Chem. 56(6), E1-E48 (2010)
80. McShane LM, Altman DG, Sauerbrei W et al. Reporting recommendations for tumor MARKer prognostic studies (REMARK). Nat. Clin. Pract. Oncol. 2, 416-422 (2005) (Pubitemid 43115010)
81. Harbeck N, Thomssen C. A new look at node-negative breast cancer. Oncologist 16(Suppl. 1), 51-60 (2011)
82. Hofmeister V, Schrama D, Becker JC. Anti-cancer therapies targeting the tumor stroma. Cancer Immunol. Immunother. 57, 1-17 (2008) (Pubitemid 350043655)
83. Schaller J, Gerber SS. The plasmin-antiplasmin system: structural and functional aspects. Cell. Mol. Life Sci. 68, 785-801 (2011)
84. Rijken DC, Lijnen HR. New insights into the molecular mechanisms of the fibrinolytic system. J. Thromb. Haemost. 7, 4-13 (2009)
85. Kantelhardt EJ, Vetter M, Schmidt M et al. Prospective evaluation of prognostic factors uPA/PAI-1 in node-negative breast cancer: Phase III NNBC3-Europe trial (AGO, GBG, EORTC-PBG) comparing 6 A FEC versus 3 A FEC/3 A docetaxel. BMC Cancer 11, 140 (2011)
86. National Center for Biotechnology Information www.ncbi.nlm.nih.gov
87. Clinicaltrials.gov www.clinicaltrials.gov
88. German Breast Group www.germanbreastgroup.de
89. WILEX AG www.wilex.com
90. Angstrom Pharmaceuticals Inc www.angstrominc.com
91. National Cancer Institute: cancer staging www.cancer.gov/cancertopics/ factsheet/ detection/staging
92. Apricus Bio www.nexmed.com
93. Bio-Quant www.bio-quant.com
94. EORTC. MINDACT www.eortc.be/services/unit/mindact/ documents/MINDACT- trial-outline.pdf
95. National Cancer Institute: TAILORx (Trial Assigning Individualized Options for Treatment) www.cancer.gov/cancertopics/factsheet/ Therapy/tailorx
96. West German Study Group www.wsg-online.com/wsg/default. aspx~ID=142&CID=2